A Study of MEDI-575 in Subjects With Recurrent Glioblastoma Multiforme
Public ClinicalTrials.gov record NCT01268566. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Study of MEDI-575 in Adult Subjects With Recurrent Glioblastoma Multiforme
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of this Phase II study is to evaluate the progression-free survival at 6 months in adult subjects with a first recurrence of Glioblastoma Multiforme who are treated with MEDI-575.
Study identification
- NCT ID
- NCT01268566
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 62 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 95 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 31, 2010
- Primary completion
- Oct 31, 2012
- Completion
- Oct 31, 2012
- Last update posted
- Apr 5, 2017
2011 – 2012
United States locations
- U.S. sites
- 12
- U.S. states
- 11
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Tucson | Arizona | — | — |
| Research Site | Los Angeles | California | — | — |
| Research Site | Stanford | California | — | — |
| Research Site | Chicago | Illinois | — | — |
| Research Site | Boston | Massachusetts | — | — |
| Research Site | Detroit | Michigan | — | — |
| Research Site | New York | New York | — | — |
| Research Site | Canton | Ohio | — | — |
| Research Site | Pittsburgh | Pennsylvania | — | — |
| Research Site | Nashville | Tennessee | — | — |
| Research Site | San Antonio | Texas | — | — |
| Research Site | Seattle | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01268566, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 5, 2017 · Synced Sep 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01268566 live on ClinicalTrials.gov.